Riskpilot← Back to searchSign inGet full accessPharma4ever A/S
A/SActiveCVR 36436573Hørkær 24, st.Engineering activities and related technical consultancy · NACE 7112Est. 201417 employeeswww.pharma4ever.com
Revenue 2024
DKK 15,5M
+1% vs 2023
EBITDA margin
20.1%
-39% vs 2023
Equity ratio
33.3%
Financial strength
Net profit 2024
DKK 2,4M
-39% vs 2023
| Revenue | DKK 15,5M | +1% |
| EBITDA | DKK 3,1M | -39% |
| Net profit | DKK 2,4M | -39% |
| Total assets | DKK 8,8M | -10% |
| Equity | DKK 2,9M | -36% |
| Employees | 17 | — |
Legal name
Pharma4ever A/S
CVR number
36436573
Legal form
Aktieselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
13. november 2014
Share capital
DKK 500.000
Employees
17 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede direktion i forening eller af den samlede bestyrelse i forening.
Company purpose
Selskabets formål er at drive virksomhed med teknisk rådgivning og hermed beslægtet virksomhed.
Address
Hørkær 24, st.
Website
www.pharma4ever.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.626 | 17.154 | 12.318 | 7.732 | 7.370 | 8.802 | 8.911 | 13.010 | 15.279 | 15.476 |
| Staff expenses | -6.014 | -13.025 | -10.107 | -6.381 | -5.890 | -6.480 | -6.676 | -9.565 | -10.203 | -12.368 |
| EBITDA | 2.613 | 4.129 | 2.212 | 1.350 | 1.480 | 2.322 | 2.235 | 3.445 | 5.076 | 3.108 |
| Depreciation & amort. | -0 | -1 | -4 | -10 | -11 | -30 | -41 | -25 | -0 | -0 |
| EBIT | 2.613 | 4.128 | 2.207 | 1.340 | 1.469 | 2.291 | 2.194 | 3.420 | 5.075 | 3.108 |
| Net financials | -2 | 5 | -11 | -10 | -7 | -13 | -3 | -12 | -3 | -5 |
| Profit before tax | 2.611 | 4.133 | 2.197 | 1.330 | 1.463 | 2.279 | 2.191 | 3.408 | 5.073 | 3.102 |
| Tax | 640 | 917 | 488 | 293 | 319 | 502 | 485 | 753 | 1.129 | 686 |
| Net profit | 1.971 | 3.217 | 1.708 | 1.037 | 1.143 | 1.777 | 1.706 | 2.655 | 3.944 | 2.416 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4.181 | 4.950 | 4.593 | 3.777 | 3.759 | 4.603 | 4.875 | 6.251 | 9.779 | 8.762 |
| Equity | 2.021 | 2.738 | 1.466 | 1.703 | 1.846 | 1.623 | 2.329 | 3.235 | 4.528 | 2.916 |
| Long-term debt | 0 | 0 | 0 | 0 | 79 | 346 | 0 | 0 | 0 | 0 |
| Short-term debt | 2.160 | 2.211 | 3.125 | 2.073 | 1.834 | 2.631 | 2.543 | 3.011 | 5.245 | 5.845 |
| Total debt | 2.160 | 2.211 | 3.125 | 2.073 | 1.912 | 2.977 | 2.543 | 3.011 | 5.245 | 5.845 |
EBITDA margin
20.1%
This company
15.8%
Market median
+27% vs market
20152024
Equity ratio
33.3%
This company
38.2%
Market median
+13% vs market
20152024
Return on equity
82.9%
This company
18.4%
Market median
+351% vs market
20152024
Net profit margin
15.6%
This company
8.1%
Market median
+93% vs market
20152024
Asset turnover
1.77×
This company
1.12×
Market median
+58% vs market
20152024
Debt / equity
2.00×
This company
0.62×
Market median
-223% vs market
20152024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2014-11-13 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PR Management | Management | 2014 | — | — |
BH Management | Management | 2014 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2015 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2015 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Andresen Holding af 29. maj 2015 ApS | Company | 50.0% | 50.0% | 2015 |
BHP Holding ApS | Company | 50.0% | 0.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
BHP Holding ApS
Pharma4ever A/S Board members of Pharma4ever A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Rønsholt Andresen | Management | 0 companies |
| Bo Hejgaard Pedersen | Management | 0 companies |
| Dorthe Andresen | Chairman | 0 companies |
| Jonas Mortensen Højslet | Chairman | 0 companies |
| Susanne Andersen | Board of Directors | 0 companies |